Search clinical trials for: AZD4316

Total 49 results

AstraZeneca

Withdrawn

Assessment of the Safety and Pharmacokinetics of Single and Multiple Oral Doses of AZD4316 in Healthy Subjects

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

Reflux

Netherlands, Belgium
AstraZeneca

Terminated

A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

Cardiovascular Disease
AstraZeneca
Parexel

Completed

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

Healthy Volunteers

United States
AstraZeneca

Completed

An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516

Healthy

Sweden
AstraZeneca

Completed

Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)

Sensitivity in Esophagus

Denmark, Sweden
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers

Renal Impairment

Bulgaria
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% (ENDEAVOR)

Heart Failure With Preserved Ejection Fraction

United States, France, Netherlands, Belgium, Taiwan, Slovakia, Japan, Czechia, Hungary, Australia, Bulgaria, Poland, Russian Federation, Brazil, Denmark, Turkey, Sweden, Canada
AstraZeneca
Parexel

Completed

A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States
AstraZeneca
Quintiles, Inc.

Completed

To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers

Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years. | Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80

United Kingdom
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386 (MAD)

Chronic Pain

United Kingdom
AstraZeneca

Completed

Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

Obesity

Sweden
AstraZeneca

Completed

Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (TOP)

Chronic Obstructive Pulmonary Disease (COPD)

Sweden, Denmark, Finland, Netherlands, Norway
AstraZeneca

Completed

Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses (MAD)

Diabetes Mellitus Type 2

Sweden
AstraZeneca

Completed

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017

Healthy

Sweden
AstraZeneca

Terminated

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure. (SATELLITE)

Heart Failure

Denmark, Finland, Netherlands, United States, Sweden
AstraZeneca

Terminated

Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee (OA19)

Pain

Bulgaria, Poland, Hungary, Finland, Canada, Slovakia, Japan
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects

Healthy

Japan
Mayo Clinic
National Center for Advancing Translational Sciences (NCATS)

Completed

MPO Inhibitor A_Zeneca for HFpEF

Heart Failure

United States
AstraZeneca

Recruiting

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. (CRESCENDO)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Denmark, Germany, South Africa, Spain, United Kingdom, Italy, Argentina, Bulgaria, Mexico, Turkey, Poland, Netherlands
AstraZeneca

Completed

A Study in Participants With Non-cirrhotic NASH With Fibrosis (COSMOS)

Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Denmark, Italy, Spain, United States, Argentina, Sweden, Mexico, Norway, Portugal
AstraZeneca

Active, not recruiting

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

Non-alcoholic Steatohepatitis (NASH)

United States
AstraZeneca
Parexel

Completed

A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease

Cardiovascular Disease

United States
AstraZeneca

Completed

Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers

Healthy

Japan
AstraZeneca

Completed

AZD1386 Japanese Multiple Ascending Dosing Study (JMAD)

Chronic Pain

Japan
AstraZeneca

Completed

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.

Healthy

Japan
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831

Cardiovascular Disease

United Kingdom
AstraZeneca

Completed

Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386

Pain

United Kingdom
AstraZeneca

Completed

Esophageal Hypersensitivity Study in Healthy Volunteers

Pain | Esophageal Sensitivity

Sweden, Denmark
University of Michigan Rogel Cancer Center

Terminated

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
University of Birmingham

Completed

Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. (IIH:DT)

Idiopathic Intracranial Hypertension

United Kingdom
AstraZeneca

Recruiting

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

Hepatic Impairment

United States
AstraZeneca

Completed

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor

United Kingdom, United States
AstraZeneca

Completed

Formulation and Food Effect Study of AZD1386 in Healthy Volunteers

Pharmacokinetics
AstraZeneca

Terminated

Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain (AVANT)

Pain | Neuropathic Pain

France, United Kingdom, Canada, Denmark
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers

Healthy

Sweden
AstraZeneca

Completed

Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)

Capsaicin Evoked Pain | Heat Sensitivity
University of Leeds

Completed

Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) (GC-SHealD)

Diabetes Mellitus, Type 2

United Kingdom
AstraZeneca

Completed

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.

T2DM With NAFLD
AstraZeneca

Completed

Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults (AZD2816)

COVID-19 | SARS-CoV-2

United Kingdom, Brazil, South Africa, Poland
AstraZeneca

Completed

Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers

Nociceptive Pain | Peripheral Neuropathic Pain

United Kingdom
AstraZeneca

Terminated

Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

Raised Intraocular Pressure

Sweden, United States, United Kingdom
AstraZeneca

Completed

Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386

Pain

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole

Healthy Volunteers

United Kingdom
University of Oxford
AstraZeneca

Completed

Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)

Iatrogenic Cushing's Disease

United Kingdom
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

Cardiovascular Disease

United States
Pablo Tebas
AstraZeneca; Inovio Pharmaceuticals; The Wistar Institute

Recruiting

dMAbs for Prevention of COVID-19

Healthy Volunteers

United States

3

Subscribe